Dublin, Ireland, December 11th, 2017 – DS Biopharma (DS), a clinical stage biopharmaceutical company, today announced receipt of allowance for a patent application in the United States of America (US). The allowance protects compositions of the Company’s second generation compound DS109, a unique 5-LOX / IL-1 beta inhibitor.
The United States Patent and Trademark Office (USPTO) has allowed the US patent application entitled “Pharmaceutically Acceptable Salts of Fatty Acids” which has the serial number 14/543,638. This will provide exclusivity for compositions of DS109 until 2034.
DS109 is being developed in both a topical and an oral dosage form intended for the treatment of inflammatory diseases in dermatology and rheumatology.
DS continues to prosecute additional DS109 patent applications in the US and other key jurisdictions.
About DS Biopharma
DS Biopharma, headquartered in Dublin, Ireland, is a privately held, clinical stage, pharmaceutical drug discovery and development company, which develops new medicines for unmet needs. The compounds under development are based on a novel bioactive lipid platform. These lipid molecules have been shown to be crucial to the pathways of several inflammatory skin diseases including Atopic Dermatitis (AD). The Company has two separate Phase 2b trials recruiting in North America at present: topical DS107 in 300 mild to moderate AD patients and oral DS107 in 300 moderate to severe AD patients. Both trial are expected to read out in Q.3 2018.
DS Biopharma: firstname.lastname@example.org, +35312933590